Clinical trial · Observational
Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor with relatively poor survival. Surgery is the first choice for the treatment of patients with early pancreatic cancer. However, the surgical approach and the extent of resection for patients with pancreatic cancer are controversial at present. The investigators optimized the procedure of standard pancreaticoduodenectomy to selective extended dissection (SED), which is based on the extra-pancreatic nerve plexus (PLX) potentially invaded by tumor. The investigators retrospectively analyzed the clinicopathological data of patients with pancreatic adenocarcinoma who underwent radical surgery in our center from 2011 to 2020. Patients who underwent standard dissection (SD) were matched 2:1 to those who underwent SED using propensity score matching (PSM). The log-rank test and cox regression model were used to analyze survival data. In addition, statistical analyses were performed for the perioperative complications, postoperative pathology and recurrence pattern.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Pancreatic Ductal | Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Selective extended dissection of pancreaticoduodenectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Selective extended dissection (SED) group
- interventionNames
- Procedure: Selective extended dissection of pancreaticoduodenectomy
- label
- Standard dissection (SD) group
Primary outcomes (1)
- measure
- Disease-free survival (DFS)
- timeFrame
- From the day the patient received surgery to the time the patient was diagnosed with postoperative recurrence, assessed up to 36 months.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: \- 1) Patients diagnosed as resectable pancreatic cancer were pathologically diagnosed as PDAC after surgery. 2\) Patients received radical surgery (R0) and had complete photos or videos of the operation. Exclusion Criteria: \- 1) The operation records as well as related photo or video data could not reflect the surgical approach and the extent of resection. 2\) Patients with incomplete clinical, pathological, imaging and follow-up information.
References
Publications (1)
- DERIVEDGuo X, Song Y, Xu P, Zhu W, Wang H, Zhou Y, Huang C, Hao J, Gao S. Selective extended dissection for pancreaticoduodenectomy is associated with better survival in pancreatic cancer patients: retrospective cohort study. Int J Surg. 2023 Jul 1;109(7):1852-1862. doi: 10.1097/JS9.0000000000000437. PMID 37195787